Foundayo (Orforglipron): What to Know About This New GLP-1 Weight Loss Pill
For the first time in decades, people looking to manage their weight have a genuinely new kind of option. On April 1, 2026, the U.S. Food and Drug Administration approved Foundayo (orforglipron), an oral once-daily pill in the GLP-1 class — and the first of its kind that can be taken at any time of day, with or without food and water. Made by Eli Lilly, this is not simply another formulation of an existing injectable treatment. It is a chemically distinct, small-molecule compound that rewrites the rulebook for how GLP-1 weight loss therapy can be delivered.
Whether you have been curious about GLP-1 pills but felt put off by injections, or you have heard the buzz around Ozempic and Wegovy and wondered if there is something simpler out there — this guide covers everything you need to know before talking to your doctor.
What Is Foundayo (Orforglipron)?
Foundayo (orforglipron) is a prescription weight management pill approved for adults living with obesity, or adults who are overweight and have at least one weight-related health condition — such as high blood pressure, high cholesterol, obstructive sleep apnea, or cardiovascular disease. It is designed to be taken once daily alongside a reduced-calorie diet and increased physical activity.
The active ingredient, orforglipron, was originally discovered by Chugai Pharmaceutical Co., Ltd. and licensed by Eli Lilly in 2018. Unlike the injectable GLP-1 therapies already on the market — such as Wegovy (semaglutide) or Zepbound (tirzepatide) — orforglipron is what scientists call a small molecule non-peptide GLP-1 receptor agonist. This distinction matters enormously for everyday users, and we will unpack exactly why below.
One detail worth knowing upfront: Foundayo was approved through the FDA’s National Priority Voucher pilot program in just 50 days — the fastest approval of a brand-new molecular entity since 2002. That speed reflects both the urgency around obesity treatment in America and the strength of the clinical data behind the pill.
How Does GLP-1 Work for Weight Loss?
To understand Foundayo, you first need to understand what a GLP-1 receptor agonist actually does inside your body. GLP-1 stands for glucagon-like peptide-1, a hormone naturally produced in your gut after you eat. It plays several important roles in metabolism.
Appetite regulation: GLP-1 signals your brain — specifically the hypothalamus — that you are full. When GLP-1 levels rise, hunger drops. You naturally feel satisfied with smaller portions, and the urge to snack between meals diminishes significantly.
Slowing gastric emptying: GLP-1 slows the rate at which food moves from your stomach into your small intestine. This prolongs the sensation of fullness after eating, reducing total calorie intake over the course of the day without requiring you to consciously restrict what you eat.
Insulin and blood sugar balance: GLP-1 helps the pancreas release the right amount of insulin in response to rising blood sugar, which is particularly beneficial for people with or at risk of type 2 diabetes. It also suppresses glucagon, a hormone that would otherwise raise blood sugar between meals.
GLP-1 pills like Foundayo mimic the action of this natural hormone, keeping these beneficial signals switched on at a consistent, therapeutic level throughout the day. The result is a sustained reduction in appetite, fewer cravings, and meaningful long-term weight loss when combined with lifestyle changes.
What makes Foundayo different from earlier GLP-1 pills is its chemical structure. Because orforglipron is a small-molecule compound rather than a peptide, the body can absorb it rapidly and reliably without requiring any special timing around food or water intake. Other GLP-1 pills must be taken first thing in the morning on an empty stomach, with a mandatory 30-minute wait before eating or drinking anything other than water. Foundayo carries none of those restrictions.
Foundayo Versus Other GLP-1 Pills: How Do They Compare?
The oral GLP-1 landscape is newer than most people realise. The Wegovy pill — oral semaglutide from Novo Nordisk — became the first FDA-approved oral GLP-1 for obesity in December 2025. Foundayo arrived just months later as the second. The two pills are often mentioned together, but they are meaningfully different.
Foundayo is a small-molecule non-peptide compound that can be taken at any time of day with or without food. The Wegovy pill is a peptide, which means it must be taken first thing in the morning on an empty stomach with a mandatory 30-minute wait before food or any drink other than water. That restriction hasn’t appeared to stop people from using it — the Wegovy pill is already estimated to be used by around 400,000 people in the US — but it does make daily dosing more demanding for people with complex morning routines or medical regimens.
In terms of efficacy, clinical trials showed Foundayo producing an average of around 12.4 percent body weight loss at the highest dose over 72 weeks. The Wegovy pill showed slightly higher results in its trials — around 16 to 17 percent. It is important to note these trials were not head-to-head comparisons, and real-world outcomes may differ based on adherence, lifestyle, and individual response. Neither pill matches the potency of the injectable GLP-1 therapies, which can produce 15 to 21 percent weight reduction. But for many people, a pill they can actually take consistently is more effective in practice than an injection they avoid.
Starting cash prices for both pills are currently the same — $149 per month for the lowest dose.
What Did the Clinical Trials Show?
Foundayo’s approval was backed by a phase 3 program called the ATTAIN trials, which enrolled over 4,500 participants across two large global studies.
ATTAIN-1 enrolled 3,127 adults with obesity or overweight who did not have type 2 diabetes. Over 72 weeks, participants on the highest dose of orforglipron who remained on treatment lost an average of 27.3 pounds — about 12.4 percent of their body weight — compared to just 2.2 pounds in the placebo group. Across all randomised participants regardless of whether they completed the trial, mean weight loss was still 11.1 percent versus 2.1 percent for placebo. Full results were published in the New England Journal of Medicine.
ATTAIN-2 enrolled over 1,600 adults with type 2 diabetes and showed meaningful weight reductions of 5.1 to 9.6 percent depending on dose, along with significant improvements in blood sugar control and cardiometabolic markers including waist circumference, blood pressure, and cholesterol. These results were published in The Lancet.
Participants also saw improvements in a range of secondary outcomes beyond weight — including waist circumference, triglycerides, HDL cholesterol, and systolic blood pressure — suggesting benefits that extend well beyond the number on the scale.
An additional study called ATTAIN-MAINTAIN found that orforglipron helped people hold onto weight they had previously lost with injectable GLP-1 therapies, opening up a potential step-down strategy for people who want to transition from weekly injections to a simpler daily pill once they have reached their target weight.
Who Is Foundayo For?
Foundayo is FDA-approved for adults with a BMI of 30 or higher, or adults with a BMI of 27 or higher who also have at least one weight-related health condition such as hypertension, type 2 diabetes, high cholesterol, or cardiovascular disease.
It is not approved for use in children, and its safety and effectiveness in younger patients have not been established. It should not be taken alongside other GLP-1 receptor agonists. People who are pregnant, planning to become pregnant, or taking oral contraceptives should discuss the treatment carefully with their provider before starting, as Foundayo may affect how birth control pills are absorbed — particularly during the first month at each dose level.
Foundayo also carries a boxed warning for potential thyroid C-cell tumors, including medullary thyroid carcinoma. It should not be used in patients with a personal or family history of this condition or multiple endocrine neoplasia syndrome type 2. Full disclosure of your medical history to your prescribing physician is essential before starting.
According to Eli Lilly’s chief scientific officer Daniel Skovronsky, Foundayo may appeal especially to people who have been hesitant about injections, or whose complex daily routines make strict fasting requirements difficult to manage. Lilly estimates that fewer than 1 in 10 Americans who could benefit from a GLP-1 treatment are currently using one — and a pill with no dosing restrictions is part of their answer to that gap.
What Are the Potential Side Effects?
Like all GLP-1 receptor agonists, Foundayo’s most commonly reported side effects are gastrointestinal. These tend to be most noticeable in the early weeks of treatment, particularly when the dose is being increased, and often improve as the body adjusts.
Common side effects include nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, and hair thinning. Rare but more serious risks include pancreatitis, gallbladder disease, and the thyroid tumor risk noted above. The safety profile is broadly consistent with other GLP-1 receptor agonists already on the market.
How Much Is GLP-1 Without Insurance?
Cost has historically been one of the biggest barriers to accessing GLP-1 weight loss therapy — with some injectables running well over $1,000 per month at full retail price. Foundayo represents a meaningful shift in that landscape. Through a pricing agreement negotiated with the U.S. government, Eli Lilly committed to keeping the entry price significantly lower than earlier GLP-1 treatments.
Without insurance, Foundayo starts at $149 per month for the lowest dose through LillyDirect. Higher maintenance doses range from $299 to $349 per month depending on the dose and refill timing — the $299 price applies only when the prescription is refilled within 45 days of the previous fill. If that window is missed, the standard price rises to $349 per month.
For context, this is considerably more affordable than the injectable GLP-1 treatments, which can exceed $1,000 per month at retail without coverage. Lilly’s Self-Pay Savings Card and free home delivery through its LillyDirect platform help reduce costs further for eligible patients.
Does Insurance Cover GLP-1 Treatments Like Foundayo?
This is one of the most common questions patients ask — and the honest answer is that it depends, and the landscape is changing quickly.
Commercial and employer-sponsored insurance: Coverage for Foundayo will vary by plan. Insurers are generally more willing to cover GLP-1 treatments when prescribed for type 2 diabetes management than for weight loss alone, since weight management has historically been viewed as elective. This perception is shifting as clinical evidence of obesity’s health impacts grows stronger. If your plan does cover Foundayo, you may pay as little as $25 per month using the official Foundayo Savings Card from Eli Lilly.
Medicare: Federal law has historically barred Medicare from covering weight-loss prescription therapies. However, under the Medicare GLP-1 Bridge program announced by CMS in December 2025, eligible Medicare Part D beneficiaries will be able to access Foundayo beginning July 1, 2026, for approximately $50 per month. This bridges to the BALANCE Model, which will expand comprehensive Medicare Part D coverage for obesity treatments from January 1, 2027.
Medicaid: Coverage varies by state. Some state programs cover anti-obesity treatments; others limit or exclude them. Patients should review their individual state plan’s formulary or contact their case manager for current details.
If your insurance does not cover Foundayo, self-pay options from LillyDirect offer a more accessible entry point than most prior GLP-1 treatments. It is also worth asking your doctor to formally document any weight-related comorbidities, as this strengthens the case for insurance approval and prior authorisation requests.
To check whether your specific plan covers Foundayo, review your insurer’s drug formulary — usually available on your plan’s website — or call the member services number on the back of your insurance card.
How to Get Foundayo?
Foundayo is a prescription treatment, which means you will need a conversation with a licensed healthcare provider before starting. You can obtain a prescription through Lilly’s own LillyDirect telehealth and pharmacy platform, which began home delivery on April 6, 2026. It is also available through telehealth providers and major U.S. retail pharmacies.
Foundayo comes in six dose strengths ranging from 0.8 mg to 17.2 mg. Patients typically begin at the lowest dose and gradually increase over several weeks in consultation with their provider. Not everyone needs to reach the highest dose to see meaningful results — your doctor will guide that process based on how your body responds and what side effects, if any, you experience.
The Bigger Picture
The approval of Foundayo marks a genuine turning point in how obesity is treated in the United States. Just a few years ago, GLP-1 therapy meant a weekly injection that had to be refrigerated and cost over $1,000 a month without coverage. Today, a once-daily pill with no food restrictions, no needles, and an entry price of $149 a month is available at your local pharmacy.
That said, Foundayo is not a magic pill. Its efficacy, while clinically meaningful, is more modest than that of the injectable agents. It works best as part of a broader commitment to sustainable lifestyle change — a reduced-calorie diet, regular physical activity, and consistent medical support. Think of it as a powerful tool in your weight management approach, not a replacement for the underlying work.
Lilly also has broader ambitions for orforglipron beyond obesity. Ongoing trials are evaluating its potential in obstructive sleep apnea, hypertension, osteoarthritis knee pain, and stress urinary incontinence. This is a compound that, if the evidence continues to build, could reshape how we treat a whole cluster of conditions tied to metabolic health.
Frequently Asked Questions
1. What is Foundayo (orforglipron) and how is it different from other GLP-1 pills?
Foundayo (orforglipron) is a once-daily oral GLP-1 receptor agonist approved by the FDA in April 2026 for weight management in adults with obesity or overweight. Unlike other GLP-1 pills such as oral semaglutide (Wegovy tablet), Foundayo is a small-molecule non-peptide compound that the body can absorb without any food or water timing restrictions. You can take it at any time of day, with or without a meal — a flexibility no other GLP-1 pill currently offers.
2. How does GLP-1 work for weight loss?
GLP-1 is a naturally occurring gut hormone that signals fullness to the brain, slows gastric emptying, and helps regulate insulin and blood sugar. GLP-1 receptor agonists like Foundayo mimic this hormone at a sustained therapeutic level, reducing appetite, limiting calorie intake, and supporting long-term weight loss when combined with diet and exercise.
3. How much weight can I expect to lose on Foundayo?
In the ATTAIN-1 phase 3 clinical trial, participants on the highest dose who remained on treatment lost an average of about 12.4 percent of their body weight — approximately 27.3 pounds — over 72 weeks, compared to less than 1 percent for those on placebo. Results vary by individual. Injectable GLP-1 therapies tend to produce greater weight loss, but many patients prefer the consistency and convenience of a pill they can actually take every day.
4. Does insurance cover GLP-1 weight loss treatments like Foundayo?
Coverage varies by plan. With commercial insurance, you may pay as little as $25 per month with Lilly’s savings card if your plan covers it. Medicare coverage is expected to begin through the GLP-1 Bridge program from July 1, 2026, at approximately $50 per month for eligible beneficiaries. Medicaid coverage varies by state. If coverage is denied, you can request a prior authorisation or appeal with documentation of weight-related health conditions from your doctor.
5. How much is GLP-1 (Foundayo) without insurance?
Without insurance, Foundayo starts at $149 per month for the lowest dose through LillyDirect. Higher maintenance doses range from $299 to $349 per month depending on the dose and refill timing. This is significantly more affordable than older injectable GLP-1 treatments, which can exceed $1,000 per month at retail without insurance.
6. Can I take Foundayo with food?
Yes — this is one of Foundayo’s defining advantages. Unlike the Wegovy pill, which must be taken on an empty stomach first thing in the morning with a 30-minute wait before food or any drink other than water, Foundayo can be taken at any time of day with or without food and with any beverages.
7. Who should not take Foundayo?
Foundayo should not be used by people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. It is not approved for children, and should not be taken alongside other GLP-1 receptor agonists. People who are pregnant, planning pregnancy, or taking oral contraceptives should consult their doctor before starting.
8. Is Foundayo the same as Ozempic or Wegovy?
No. Ozempic and Wegovy both contain semaglutide, a peptide-based compound administered by injection (or in Wegovy’s newer form, a pill with strict fasting requirements). Foundayo contains orforglipron, a chemically distinct small-molecule compound with no food or water restrictions. It also targets GLP-1 receptors differently from Lilly’s own injectable treatments Mounjaro and Zepbound, which target both GLP-1 and GIP receptors.
9. Where can I get Foundayo?
Foundayo is available by prescription through Lilly’s LillyDirect platform with free home delivery, major U.S. retail pharmacies, and telehealth providers. You will need to speak with a licensed healthcare provider to obtain a prescription and determine whether Foundayo is appropriate for your health profile and goals.
